Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis
DOI:10.3969/j.issn.1001-5256.2021.08.018
- VernacularTitle:直接抗病毒药物改善HCV相关肝细胞癌患者远期预后效果的Meta分析
- Author:
Quan ZHOU
1
;
Lihui YANG
;
Fangqing JIANG
Author Information
1. The First Hospital of Changsha, Changsha 410000, China
- Publication Type:Research Article
- Keywords:
Hepatitis C;
Direct-Acting Antiviral;
Carcinoma, Hepatocellular;
Meta-Analysis as Topic
- From:
Journal of Clinical Hepatology
2021;37(8):1836-1840.
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo systematically evaluate the difference in recurrence-free survival rate, hepatocellular carcinoma (HCC) recurrence rate, all-cause mortality rate, and liver-related mortality rate between hepatitis C-related HCC patients receiving oral direct-acting antiviral (DAA) and those receiving non-DAA (NDAA) treatment regimen. MethodsCNKI, Wanfang Data, VIP, CBM, PubMed, Embase, and Cochrane Library were searched for Cohort studies of DAA in the treatment of hepatitis C-related HCC patients published before December 2020, and quality assessment and meta-analysis were performed. ResultsA total of 10 cohort studies were included in this study, with 3108 patients in total. The meta-analysis showed that compared with NDAA regimen, DAA treatment significantly increased recurrence-free survival rate (risk ratio ［RR］=1.38, 95% confidence interval ［CI］: 1.10-1.72, P=0.005) and significantly reduced HCC recurrence rate (RR=0.52, 95%CI: 0.42-0.63, P＜0.000 01), all-cause mortality rate (RR=0.42, 95%CI: 0.32-0.55, P＜0.000 01), and liver-related mortality rate (RR=0.37, 95%CI: 0.18-0.76, P=0.007) in hepatitis C-related HCC patients. ConclusionDAA treatment is beneficial and safe for hepatitis C-related HCC patients.
